Rationale, design, and statistical analysis plan for a randomized, double-blind, placebo-controlled trial of Limosilactobacillus reuteri to support mother-infant bonding and maternal socioemotional functioning in postpartum women at increased risk for postpartum depression.
Level 5 - mechanism / opinion, no new human data
Clinical trial protocol and statistical analysis plan; no comparative efficacy results are reported.
PubMed 42398703 · doi:10.1016/j.cct.2026.108399
What was done
This paper describes the rationale, design, and statistical analysis plan for a randomized, double-blind, placebo-controlled proof-of-concept trial of Limosilactobacillus reuteri versus placebo taken once daily for 6 weeks by postpartum mothers aged ≥18 years at elevated risk for postpartum depression. Randomization was stratified by delivery mode (vaginal vs. Cesarean section). The primary endpoint is mother-infant bonding quality at Week 6; secondary endpoints are maternal mental health, impulse control, and emotion recognition at Week 6, with salivary oxytocin at Week 2 as a mechanistic endpoint.
What was found
Forty-six participants were enrolled and randomized (mean age ± SD: 34.3 ± 4.5 years), and 38 (82.6%) completed the Week-6 visit. The abstract provides only baseline enrollment and completion numbers; no efficacy or between-group outcome results are reported.
Why it matters
This paper describes the protocol and methodology for testing whether gut microbiome modulation can stimulate endogenous oxytocin pathways to support maternal mental health and bonding in at-risk postpartum women.
Limits
This report contains no trial outcome or efficacy data. The sample size is small (46 randomized, 38 completed), appropriate only for a proof-of-concept feasibility study.
Cited by
- context Limosilactobacillus reuteri yogurt culture increases systemic oxytocin levels.